- Home
- GYRE vs OLO Comparison
GYRE vs OLO Comparison
Compare GYRE & OLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- OLO
- Stock Information
- Founded
- GYRE 2002
- OLO 2005
- Country
- GYRE United States
- OLO United States
- Employees
- GYRE N/A
- OLO N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- OLO Major Banks
- Sector
- GYRE Health Care
- OLO Finance
- Exchange
- GYRE Nasdaq
- OLO Nasdaq
- Market Cap
- GYRE 990.4M
- OLO 1.1B
- IPO Year
- GYRE N/A
- OLO 2021
- Fundamental
- Price
- GYRE $7.72
- OLO $6.04
- Analyst Decision
- GYRE
- OLO Buy
- Analyst Count
- GYRE 0
- OLO 3
- Target Price
- GYRE N/A
- OLO $8.67
- AVG Volume (30 Days)
- GYRE 221.1K
- OLO 1.2M
- Earning Date
- GYRE 03-17-2025
- OLO 05-06-2025
- Dividend Yield
- GYRE N/A
- OLO N/A
- EPS Growth
- GYRE N/A
- OLO N/A
- EPS
- GYRE 0.05
- OLO N/A
- Revenue
- GYRE $105,757,000.00
- OLO $284,938,000.00
- Revenue This Year
- GYRE $51.85
- OLO $17.50
- Revenue Next Year
- GYRE $29.83
- OLO $18.43
- P/E Ratio
- GYRE $155.02
- OLO N/A
- Revenue Growth
- GYRE N/A
- OLO 24.82
- 52 Week Low
- GYRE $7.00
- OLO $4.20
- 52 Week High
- GYRE $19.00
- OLO $8.35
- Technical
- Relative Strength Index (RSI)
- GYRE 33.88
- OLO 36.01
- Support Level
- GYRE $8.65
- OLO $6.22
- Resistance Level
- GYRE $9.50
- OLO $6.58
- Average True Range (ATR)
- GYRE 1.02
- OLO 0.20
- MACD
- GYRE -0.24
- OLO 0.01
- Stochastic Oscillator
- GYRE 12.81
- OLO 12.10
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.